Startseite Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone

  • Yicong Yin , Chaochao Ma , Songlin Yu , Wenjing Liu , Danchen Wang , Tingting You , Qian Cheng und Ling Qiu EMAIL logo
Veröffentlicht/Copyright: 28. Oktober 2019
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 58 Heft 1

Abstract

Background

This study aimed to quantify and compare serum aldosterone (sALD) levels through three different chemiluminescence immunoassays (CLIAs) and liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis.

Methods

Serum samples from 221 patients with suspected primary aldosteronism (PA) were retrospectively included in this study conducted at the Peking Union Medical College Hospital from June to August in 2017. sALD levels were determined using the LC-MS/MS method and three different CLIA systems, viz., DiaSorin® XL, iSYS and Auto Lumo A2000. Pooled fresh serum samples were used for recalibration. Passing-Bablok regression analysis, correlation matrix, and Bland-Altman plots were used to evaluate the concurrence among ALD levels determined using the three CLIAs.

Results

Within-laboratory precision of the four assays ranged from 2.1% to 9.4%, except the coefficient variation (CV) of one of the CLIAs, which exceeded 20.0% for samples with low sALD levels. sALD levels determined using LC-MS/MS were significantly lower than those determined using the other three CLIAs (p < 0.0001). Spearman’s correlation coefficient of the four assays ranged from 0.745 to 0.950 (p < 0.0001). The Bland-Altman plot showed that the average bias (%) for the three CLIAs and LC-MS/MS ranged from −69.3 to −49.2. After recalibration, this correlation did not improve among the assays. However, the bias and bias percentage at the medical decision level improved between LC-MS/MS and DiaSorin® XL/iSYS.

Conclusions

Significant inconsistencies between the results of CLIAs and LC-MS/MS indicate that different sALD measures cannot be used interchangeably.

Keywords: aldosterone; chemiluminescence immunoassay; liquid chromatography tandem mass spectrometry; inconsistency; primary aldosteronism; recalibration
Corresponding author: Prof. Ling Qiu, Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. China, Phone: +86-01069159712, Fax: +86-01069159712
aYicong Yin, Chaochao Ma and Songlin Yu contributed equally to this work.

Acknowledgments

The authors thank the participants, primary-care physicians and nurses participating in the survey.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This study was funded by the National Natural Science Foundation of China, Funder Id: http://dx.doi.org/10.13039/501100001809, (81702060) and by research grants from the China National Clinical Key Subject Program.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854–9.10.1210/jc.85.8.2854Suche in Google Scholar

2. Kline GA, Prebtani AP, Leung AA, Schiffrin EL. Primary aldosteronism: a common cause of resistant hypertension. Can Med Assoc J 2017;189:E773–8.10.1503/cmaj.161486Suche in Google Scholar PubMed PubMed Central

3. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J, Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17:349–52.10.1038/sj.jhh.1001554Suche in Google Scholar PubMed

4. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892–6.10.1161/01.HYP.0000040261.30455.B6Suche in Google Scholar

5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243–8.10.1016/j.jacc.2005.01.015Suche in Google Scholar PubMed

6. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005;90:5070–6.10.1210/jc.2005-0681Suche in Google Scholar PubMed

7. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:80–5.10.1001/archinternmed.2007.33Suche in Google Scholar PubMed

8. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008;19:88–90.10.1016/j.tem.2008.01.006Suche in Google Scholar PubMed

9. Catena C, Colussi G, Sechi LA. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol 2013;168:C1–5.10.1530/EJE-12-0899Suche in Google Scholar PubMed

10. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010;23:1253–60.10.1038/ajh.2010.169Suche in Google Scholar PubMed

11. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016;101:1889–916.10.1210/jc.2015-4061Suche in Google Scholar PubMed

12. Stabler TV, Siegel AL. Chemiluminescence immunoassay of aldosterone in serum. Clin Chem 1991;37:1987–9.10.1093/clinchem/37.11.1987Suche in Google Scholar

13. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004;50:1650–5.10.1373/clinchem.2004.033159Suche in Google Scholar PubMed

14. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006;52:1749–55.10.1373/clinchem.2006.068502Suche in Google Scholar PubMed

15. Burrello J, Monticone S, Buffolo F, Lucchiari M, Tetti M, Rabbia F, et al. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. J Hypertens 2016;34:920–7.10.1097/HJH.0000000000000880Suche in Google Scholar PubMed

16. Van Der Gugten JG, Dubland J, Liu HF, Wang A, Joseph C, Holmes DT. Determination of serum aldosterone by liquid chromatography and tandem mass spectrometry: a liquid-liquid extraction method for the ABSCIEX API-5000 mass spectrometry system. J Clin Pathol 2012;65:457–62.10.1136/jclinpath-2011-200564Suche in Google Scholar PubMed

17. Turpeinen U, Hamalainen E, Stenman UH. Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862:113–8.10.1016/j.jchromb.2007.11.005Suche in Google Scholar PubMed

18. Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl M, et al. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem 2016;62:514–24.10.1373/clinchem.2015.251199Suche in Google Scholar PubMed

19. Hinchliffe E, Carter S, Owen LJ, Keevil BG. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;913–914:19–23.10.1016/j.jchromb.2012.11.013Suche in Google Scholar PubMed

20. Yin Y, Yu S, Qiu L, Wang X, Wang D, Ma C, et al. Establishment of a rapid and simple liquid chromatography tandem mass spectrometry method for measuring aldosterone in urine. J Chromatogr B Analyt Technol Biomed Life Sci 2019;1113:84–90.10.1016/j.jchromb.2019.03.012Suche in Google Scholar PubMed

21. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491–500.10.1080/00365519950185229Suche in Google Scholar PubMed

22. Mayo Clinic Laboratories. Available at: https://www.mayocliniclabs.com.Suche in Google Scholar

23. Cheng X, Yu S, Jin C, Han S, Hu Y, Zhang K, et al. Comparison of three different assays for measuring thyroglobulin and thyroglobulin antibodies in patients with chronic lymphocytic thyroiditis. Clin Biochem 2017;50:1183–7.10.1016/j.clinbiochem.2017.08.004Suche in Google Scholar PubMed

24. Ray JA, Kushnir MM, Palmer J, Sadjadi S, Rockwood AL, Meikle AW. Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC-MS/MS and comparison with commercial immunoassays. J Chromatogr B Analyt Technol Biomed Life Sci 2014;970:102–7.10.1016/j.jchromb.2014.08.042Suche in Google Scholar PubMed

25. Lam L, Chiu WW, Davidson JS. Overestimation of aldosterone by immunoassay in renal impairment. Clin Chem 2016;62: 890–1.10.1373/clinchem.2016.255737Suche in Google Scholar PubMed

26. Blocki F, Zierold C, Olson G, Seeman J, Cummings S, Bonelli F. In defense of aldosterone measurement by immunoassay: a broader perspective. Clin Chem Lab Med 2017;55:e87–9.10.1515/cclm-2016-0707Suche in Google Scholar PubMed

27. Wu AH, French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin Chim Acta 2013;420:4–10.10.1016/j.cca.2012.10.026Suche in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0706).

Received: 2019-04-22
Accepted: 2019-07-22
Published Online: 2019-10-28
Published in Print: 2019-12-18

©2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Reflex TSH strategy: the good, the bad and the ugly
  4. Review
  5. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
  6. Mini Review
  7. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
  8. Opinion Paper
  9. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?
  10. EFLM Paper
  11. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  12. General Clinical Chemistry and Laboratory Medicine
  13. Pre-, post- or no acidification of urine samples for calcium analysis: does it matter?
  14. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis
  15. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
  16. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers
  17. Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
  18. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays
  19. Method comparison of four clinically available assays for serum free light chain analysis
  20. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
  21. Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation
  22. Reference Values and Biological Variations
  23. A study on reference interval transference via linear regression
  24. Cancer Diagnostics
  25. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer
  26. Cardiovascular Diseases
  27. Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination
  28. Acknowledgment
  29. Letters to the Editor
  30. Are icteric and lipemic indices reliable to screen for hyperbilirubinemia and hypertriglyceridemia?
  31. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays
  32. Assessment of complement interference in anti-Müllerian hormone immunoassays
  33. Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution
  34. Results of the second external quality assessment for human papillomavirus genotyping in Shanghai, China
  35. Development of suitable external quality control material for G6PD deficiency screening with the fluorescent spot test
  36. Non-linearity in commercially available lipase assays: still gaps to close
  37. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential
  38. Congress Abstracts
  39. 11th National Scientifc Congress SPML
https://doi.org/10.1515/cclm-2019-0706
Schlagwörter für diesen Artikel
aldosterone; chemiluminescence immunoassay; liquid chromatography tandem mass spectrometry; inconsistency; primary aldosteronism; recalibration

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Reflex TSH strategy: the good, the bad and the ugly
  4. Review
  5. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
  6. Mini Review
  7. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
  8. Opinion Paper
  9. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?
  10. EFLM Paper
  11. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  12. General Clinical Chemistry and Laboratory Medicine
  13. Pre-, post- or no acidification of urine samples for calcium analysis: does it matter?
  14. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis
  15. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
  16. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers
  17. Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
  18. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays
  19. Method comparison of four clinically available assays for serum free light chain analysis
  20. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
  21. Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation
  22. Reference Values and Biological Variations
  23. A study on reference interval transference via linear regression
  24. Cancer Diagnostics
  25. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer
  26. Cardiovascular Diseases
  27. Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination
  28. Acknowledgment
  29. Letters to the Editor
  30. Are icteric and lipemic indices reliable to screen for hyperbilirubinemia and hypertriglyceridemia?
  31. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays
  32. Assessment of complement interference in anti-Müllerian hormone immunoassays
  33. Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution
  34. Results of the second external quality assessment for human papillomavirus genotyping in Shanghai, China
  35. Development of suitable external quality control material for G6PD deficiency screening with the fluorescent spot test
  36. Non-linearity in commercially available lipase assays: still gaps to close
  37. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential
  38. Congress Abstracts
  39. 11th National Scientifc Congress SPML
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 28.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0706/html
Button zum nach oben scrollen